ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer
نویسندگان
چکیده
منابع مشابه
Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer.
The additional benefit of positron emission tomography (PET) in the initial staging of non-small cell lung cancer (NSCLC) has generated interest in 18F-fluorodeoxyglucose (FDG) PET as a means of defining the extent of primary lung tumour for radiotherapy treatment planning (RTP). A review of published data suggests that PET results in a reduction in the CT-derived GTV for NSCLC primary target v...
متن کاملMultimodality treatment in locally advanced non-small cell lung cancer.
Prognosis in patients with locally advanced non-small cell lung cancer (NSCLC) is poor (five year survival rate of 5% [1]). Radiotherapy (RT), chemotherapy (CT) and surgery (S), as single modality therapeutical approaches are unable to eradicate locoregional disease and to control systemic microscopic disease. Concurrent chemoradiation (CTRT) is at present time deemed to be the standard of care...
متن کاملNeoadjuvant chemotherapy in locally advanced non-small cell lung cancer.
OBJECTIVE The objective of this study was to evaluate the role of neoadjuvant chemotherapy in the treatment of locally advanced non small cell lung cancer (NSCLC) followed by radiotherapy versus radiotherapy alone. MATERIAL AND METHODS Sixty nine patients were randomized to chemotherapy (group A) or radiotherapy alone (group B). The induction chemotherapy consists of cisplatin (80 mg/m2) day ...
متن کاملPemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), in accordance with the licensed indication, based upon the evidence submission from the manufacturer (Eli Lilly) to the National Institute for Health and Cl...
متن کاملGefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in accordance with the licensed indication, based upon the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Radiotherapy and Oncology
سال: 2018
ISSN: 0167-8140
DOI: 10.1016/j.radonc.2018.02.023